デフォルト表紙
市場調査レポート
商品コード
957665

がん遺伝子治療の世界市場

Cancer Gene Therapy

出版日: | 発行: Global Industry Analysts, Inc. | ページ情報: 英文 129 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=110.66円

ご注意:Single user licenseはDRM(デジタル著作権管理システム)付PDFとなります。
PDFの閲覧には Adobe Digital Editions (無償)のインストールが必要となります。
認証されたPC上のみでの閲覧と、1回のプリントアウトが可能となっております。

がん遺伝子治療の世界市場
出版日: 2021年04月01日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 129 Pages
納期: 即日から翌営業日
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

世界のがん遺伝子治療の市場規模は、分析期間(2020年~2027年)に29.6%のCAGRで成長する見通しで、2020年の6億1,190万米ドルから2027年には38億米ドルに達すると予測されています。当レポートで分析されているセグメントの1つである腫瘍溶解性ウイルス療法は、分析期間中に30.3%の年率で成長し、18億米ドルに達すると予測されています。

当レポートは、世界のがん遺伝子治療市場について調査しており、市場シェア、動向や見通し、成長要因、地域別の市場分析、競合情勢、主要企業のプロファイル等の情報を提供しています。

調査対象企業の例

  • Adaptimmune Therapeutics plc
  • Advantagene, Inc.
  • Altor Bioscience (a NANT Company)
  • Anchiano Therapeutics, Inc.
  • bluebird bio, Inc.
  • Genelux Corporation
  • GlaxoSmithKline PLC
  • Merck & Co., Inc.
  • OncoGenex Pharmaceuticals, Inc.
  • Shanghai Sunway Biotech Co., Ltd.
  • Shenzhen SiBiono GeneTech Co., Ltd.
  • ZIOPHARM Oncology, Inc.

目次

I. イントロダクション、調査手法、調査範囲

II. エグゼクティブサマリー

  • 市場概要
    • Covid-19の影響と迫り来る世界の景気後退
  • 主要企業
  • 動向と成長要因
  • 世界市場の見通し

III. 市場分析

  • 地域別市場分析
  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

IV. 競合

  • 企業プロファイル:42社
目次
Product Code: MCP10864

Abstract:

Global Cancer Gene Therapy Market to Reach $3.8 Billion by 2027

Amid the COVID-19 crisis, the global market for Cancer Gene Therapy estimated at US$611.9 Million in the year 2020, is projected to reach a revised size of US$3.8 Billion by 2027, growing at a CAGR of 29.6% over the analysis period 2020-2027. Oncolytic Virotherapy, one of the segments analyzed in the report, is projected to record a 30.3% CAGR and reach US$1.8 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Gene Transfer Therapy segment is readjusted to a revised 28.1% CAGR for the next 7-year period.

The U.S. Market is Estimated at $183.8 Million, While China is Forecast to Grow at 28.7% CAGR

The Cancer Gene Therapy market in the U.S. is estimated at US$183.8 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$641.9 Million by the year 2027 trailing a CAGR of 28.7% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 26.7% and 25.3% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 20.7% CAGR.

Gene-Induced Immunotherapy Segment to Record 30.5% CAGR

In the global Gene-Induced Immunotherapy segment, USA, Canada, Japan, China and Europe will drive the 30.5% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$89.5 Million in the year 2020 will reach a projected size of US$575.9 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$447 Million by the year 2027.

Select Competitors (Total 42 Featured) -

  • Adaptimmune Therapeutics plc
  • Advantagene, Inc.
  • Altor Bioscience (a NANT Company)
  • Anchiano Therapeutics, Inc.
  • bluebird bio, Inc.
  • Genelux Corporation
  • GlaxoSmithKline PLC
  • Merck & Co., Inc.
  • OncoGenex Pharmaceuticals, Inc.
  • Shanghai Sunway Biotech Co., Ltd.
  • Shenzhen SiBiono GeneTech Co., Ltd.
  • ZIOPHARM Oncology, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Current & Future Analysis for Cancer Gene Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 2: World Historic Review for Cancer Gene Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 3: World 15-Year Perspective for Cancer Gene Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027
    • TABLE 4: World Current & Future Analysis for Oncolytic Virotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 5: World Historic Review for Oncolytic Virotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 6: World 15-Year Perspective for Oncolytic Virotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 7: World Current & Future Analysis for Gene Transfer Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 8: World Historic Review for Gene Transfer Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 9: World 15-Year Perspective for Gene Transfer Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 10: World Current & Future Analysis for Gene-Induced Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 11: World Historic Review for Gene-Induced Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 12: World 15-Year Perspective for Gene-Induced Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

  • UNITED STATES
    • TABLE 13: USA Current & Future Analysis for Cancer Gene Therapy by Segment - Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 14: USA Historic Review for Cancer Gene Therapy by Segment - Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 15: USA 15-Year Perspective for Cancer Gene Therapy by Segment - Percentage Breakdown of Value Sales for Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy for the Years 2012, 2020 & 2027
  • CANADA
    • TABLE 16: Canada Current & Future Analysis for Cancer Gene Therapy by Segment - Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 17: Canada Historic Review for Cancer Gene Therapy by Segment - Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 18: Canada 15-Year Perspective for Cancer Gene Therapy by Segment - Percentage Breakdown of Value Sales for Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy for the Years 2012, 2020 & 2027
  • JAPAN
    • TABLE 19: Japan Current & Future Analysis for Cancer Gene Therapy by Segment - Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 20: Japan Historic Review for Cancer Gene Therapy by Segment - Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 21: Japan 15-Year Perspective for Cancer Gene Therapy by Segment - Percentage Breakdown of Value Sales for Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy for the Years 2012, 2020 & 2027
  • CHINA
    • TABLE 22: China Current & Future Analysis for Cancer Gene Therapy by Segment - Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 23: China Historic Review for Cancer Gene Therapy by Segment - Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 24: China 15-Year Perspective for Cancer Gene Therapy by Segment - Percentage Breakdown of Value Sales for Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy for the Years 2012, 2020 & 2027
  • EUROPE
    • TABLE 25: Europe Current & Future Analysis for Cancer Gene Therapy by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 26: Europe Historic Review for Cancer Gene Therapy by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 27: Europe 15-Year Perspective for Cancer Gene Therapy by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027
    • TABLE 28: Europe Current & Future Analysis for Cancer Gene Therapy by Segment - Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 29: Europe Historic Review for Cancer Gene Therapy by Segment - Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 30: Europe 15-Year Perspective for Cancer Gene Therapy by Segment - Percentage Breakdown of Value Sales for Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy for the Years 2012, 2020 & 2027
  • FRANCE
    • TABLE 31: France Current & Future Analysis for Cancer Gene Therapy by Segment - Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 32: France Historic Review for Cancer Gene Therapy by Segment - Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 33: France 15-Year Perspective for Cancer Gene Therapy by Segment - Percentage Breakdown of Value Sales for Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy for the Years 2012, 2020 & 2027
  • GERMANY
    • TABLE 34: Germany Current & Future Analysis for Cancer Gene Therapy by Segment - Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 35: Germany Historic Review for Cancer Gene Therapy by Segment - Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 36: Germany 15-Year Perspective for Cancer Gene Therapy by Segment - Percentage Breakdown of Value Sales for Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy for the Years 2012, 2020 & 2027
  • ITALY
    • TABLE 37: Italy Current & Future Analysis for Cancer Gene Therapy by Segment - Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 38: Italy Historic Review for Cancer Gene Therapy by Segment - Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 39: Italy 15-Year Perspective for Cancer Gene Therapy by Segment - Percentage Breakdown of Value Sales for Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy for the Years 2012, 2020 & 2027
  • UNITED KINGDOM
    • TABLE 40: UK Current & Future Analysis for Cancer Gene Therapy by Segment - Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 41: UK Historic Review for Cancer Gene Therapy by Segment - Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 42: UK 15-Year Perspective for Cancer Gene Therapy by Segment - Percentage Breakdown of Value Sales for Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy for the Years 2012, 2020 & 2027
  • REST OF EUROPE
    • TABLE 43: Rest of Europe Current & Future Analysis for Cancer Gene Therapy by Segment - Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 44: Rest of Europe Historic Review for Cancer Gene Therapy by Segment - Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 45: Rest of Europe 15-Year Perspective for Cancer Gene Therapy by Segment - Percentage Breakdown of Value Sales for Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy for the Years 2012, 2020 & 2027
  • ASIA-PACIFIC
    • TABLE 46: Asia-Pacific Current & Future Analysis for Cancer Gene Therapy by Segment - Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 47: Asia-Pacific Historic Review for Cancer Gene Therapy by Segment - Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 48: Asia-Pacific 15-Year Perspective for Cancer Gene Therapy by Segment - Percentage Breakdown of Value Sales for Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy for the Years 2012, 2020 & 2027
  • REST OF WORLD
    • TABLE 49: Rest of World Current & Future Analysis for Cancer Gene Therapy by Segment - Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 50: Rest of World Historic Review for Cancer Gene Therapy by Segment - Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 51: Rest of World 15-Year Perspective for Cancer Gene Therapy by Segment - Percentage Breakdown of Value Sales for Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy for the Years 2012, 2020 & 2027

IV. COMPETITION

  • Total Companies Profiled: 42